Stay updated on Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedIn the Taiwan locations list, the Taoyuan District entry was removed and replaced with Taoyuan, Taiwan, 333, preserving the same site code. This reflects a standardization of the city name in the study's locations.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page’s footer revision/version number was updated from v3.5.2 to v3.5.3, reflecting a minor technical update with no change to the displayed study record content.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check40 days agoChange DetectedThe study location entry was updated from Padua, Veneto, Italy, 35128 to Padova, Veneto, Italy, 35128.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded Hepatocellular carcinoma as the condition, included the Genetic and Rare Diseases Information Center as a resource, and updated the location entry from Napoli to Naples, Campania, Italy (80131) with revision to v3.5.0.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No study content or usability aspects appear to be affected.SummaryDifference0.0%

Stay in the know with updates to Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.